J.R., S.M.W.H., D.S., A.C.F., M.S.K., and F.K. are independent employees of VITIS Healthcare Group and received research funding from Advanz Pharma Germany GmbH. S.M.W.H. has received research and travel grants from Astellas, Merck, and Tillotts; research grants from Basilea, Gilead, and 3 M; travel grants from Pfizer; and lecture honoraria from Astellas, Merck, and Tillotts. O.W. has received research grants, speaker fees or travel grants from Amgen, Alexion, Astellas, AstraZeneca, Basilea, Biotest, Bristol-Myers Squibb, Correvio, Chiesi, Gilead, GSK, Hexal, Janssen, Dr. F. Köhler Chemie, MSD, Novartis, Roche, Pfizer, Sanofi, TEVA and UCB. O. Witzke is a member of the DGfN, DTG, RWGIM, DGMI and a member of the executive board of the DGI. M.J.G.T.V. has received speaker fees from Merck/MSD, 3 M, Ferring, Astellas, Uniklinik Karlsruhe, Uniklinik Köln, Akademie für Infektionsmedizin, Klinikum Essen, Pfizer, Universitätsklinikum Heidelberg, Uniklinik Frankfurt, Landesärztekammer Hessen, Janssen, Institute Merieux, Forum für medizinische Fortbildung GmbH, Universitätsklinikum Freiburg, Berliner Dialyseminar, ADKA, Falk Foundation, St Johannes Hospital, DiaLog Service, CED Service, Ärztekammer Niedersachsen, St Josef Hospital, Limbach Gruppe SE, SUMIT OXFORD Ltd, EUMEDICA, KIT Kongress, Tillotts Pharma, Helios Kliniken, Lahn-Dill Kliniken, Gilead, and Klinikum Leverkusen. O.A.C. has received grants or contracts from iMi, iHi, DFG, BMBF, Cidara, DZIF, EU-DG RTD, F2G, Gilead, Med-Pace, MSD, Mundipharma, Octapharma, Pfizer and Scynexis, received consulting fees from Abbvie, AiCuris, Basilea, Biocon, Cidara, Seqirus, Gilead, GSK, IQVIA, Janssen, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Mundipharma, Noxxon, Octapharma, Pardes, Partner Therapeutics, Pfizer, PSI, Scynexis, Seres, Elion Therapeutics and Melinta, received payment or honoraria from Abbott, Abbvie, Akademie für Infektionsmedizin, Al-Jazeera Pharmaceuticals/Hikma, amedes, AstraZeneca, Deutscher Ärzteverlag, Gilead, GSK, Grupo Biotoscana/United Medical/Knight, Ipsen Pharma, Medscape/WebMD, MedUpdate, MSD, Moderna, Mundipharma, Noscendo, Paul-Martini-Stiftung, Pfizer, Sandoz, Seqirus, Shionogi, streamedup!, Touch Independent and Vitis, received payment for expert testimony from Cidara, and participated on a Data Safety Monitoring Board or Advisory Board for Boston Strategic Partners, Cidara, IQVIA, Janssen, MedPace, PSI, Pulmocide, Shionogi, The Prime Meridian Group, Vedanta Biosciences, AstraZeneca and Melinta.